A lucrative licensing agreement deal was announced on 12 October between US-based Karyopharm Therapeutics and Japan’s Ono Pharmaceutical for the development and commercialization of Karyopharm’s lead novel compound selinexor and KPT-8602, which are indicated for all oncology indications for Japan, South Korea, Taiwan, Hong Kong and AESEAN countries.
Ono Pharmaceutical is well-respected Japanese company for commercialization and partnerships and has had a total of 29 licensing agreement and partnership deals over the last five years. The graph below shows a sharp peak in these deals for Ono Pharmaceutical in 2017 with a total of eight licensing agreements and partnership deals.
Go deeper with GlobalData
While the US still leads the way in terms of licensing agreements and partnership deals, Japanese companies like Ono Pharmaceutical have found a strong position the market.
Source: GlobalData Pharma Intelligence Center, Deals Database [accessed October 2017]
